 InGeneron's technologies enable the preparation of adipose-derived regenerative cells (ADRC) that contain progenitor and stem cells in humans and animals for autologous use.InGeneron was founded in 2006, through a recapitalization of aDEPtas, Inc. in Houston, Texas with the focus on translating fundamental research in the regenerative medicine field into clinical practice.Over 40 peer-reviewed studies have been published by InGeneron's team in collaboration with various renowned academic facilities.